PL1619180T3 - ANTAGONISTA CaSR - Google Patents

ANTAGONISTA CaSR

Info

Publication number
PL1619180T3
PL1619180T3 PL04729243T PL04729243T PL1619180T3 PL 1619180 T3 PL1619180 T3 PL 1619180T3 PL 04729243 T PL04729243 T PL 04729243T PL 04729243 T PL04729243 T PL 04729243T PL 1619180 T3 PL1619180 T3 PL 1619180T3
Authority
PL
Poland
Prior art keywords
casr antagonist
casr
antagonist
Prior art date
Application number
PL04729243T
Other languages
English (en)
Inventor
Yuko Shinagawa
Teruhiko Inoue
Toshihiro Kiguchi
Taku Ikenogami
Naoki Ogawa
Kenji Fukuda
Takashi Nakagawa
Masanori Shindo
Yuki Soejima
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PL1619180T3 publication Critical patent/PL1619180T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
PL04729243T 2003-04-23 2004-04-23 ANTAGONISTA CaSR PL1619180T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003119131 2003-04-23
PCT/JP2004/005886 WO2004094362A1 (ja) 2003-04-23 2004-04-23 CaSRアンタゴニスト
EP04729243A EP1619180B1 (en) 2003-04-23 2004-04-23 CaSR ANTAGONIST

Publications (1)

Publication Number Publication Date
PL1619180T3 true PL1619180T3 (pl) 2010-05-31

Family

ID=33308093

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04729243T PL1619180T3 (pl) 2003-04-23 2004-04-23 ANTAGONISTA CaSR

Country Status (31)

Country Link
US (4) US7304174B2 (pl)
EP (3) EP2308828A3 (pl)
JP (1) JP3751312B2 (pl)
KR (1) KR100696927B1 (pl)
CN (2) CN100577633C (pl)
AR (1) AR044075A1 (pl)
AT (1) ATE452121T1 (pl)
AU (1) AU2004232604C1 (pl)
BR (1) BRPI0407097A (pl)
CA (1) CA2513738C (pl)
CL (1) CL2004000868A1 (pl)
CO (1) CO5640091A2 (pl)
CY (1) CY1109880T1 (pl)
DE (1) DE602004024668D1 (pl)
DK (1) DK1619180T3 (pl)
ES (1) ES2337576T3 (pl)
HK (1) HK1083096A1 (pl)
HR (1) HRP20100042T1 (pl)
IL (1) IL169575A (pl)
MX (1) MXPA05007609A (pl)
MY (1) MY138734A (pl)
NO (1) NO20054868L (pl)
NZ (1) NZ541188A (pl)
PE (1) PE20050460A1 (pl)
PL (1) PL1619180T3 (pl)
PT (1) PT1619180E (pl)
RU (1) RU2315036C2 (pl)
SI (1) SI1619180T1 (pl)
TW (1) TWI329628B (pl)
WO (1) WO2004094362A1 (pl)
ZA (1) ZA200505587B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP1630157A4 (en) * 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
JP2007522148A (ja) * 2004-02-06 2007-08-09 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
WO2007124465A2 (en) * 2006-04-20 2007-11-01 Amgen Inc. Stable emulsion formulations
ES2449340T3 (es) 2007-03-30 2014-03-19 Amgen Inc. Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales
PL2292592T3 (pl) * 2008-06-05 2013-01-31 Asahi Kasei Pharma Corp Związki sulfonamidowe i ich zastosowanie
NZ593676A (en) * 2008-12-24 2012-06-29 Daiichi Sankyo Co Ltd Calcium-sensing receptor antagonists
JP5551614B2 (ja) * 2008-12-24 2014-07-16 第一三共株式会社 環状アミン化合物
WO2010103429A1 (en) * 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
CN102365261A (zh) 2009-03-26 2012-02-29 日本烟草产业株式会社 制备羧酸化合物的方法
WO2010113860A1 (ja) * 2009-03-31 2010-10-07 第一三共株式会社 ビフェニル－環状アミン化合物
WO2010136035A2 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
US8765676B2 (en) 2009-05-27 2014-07-01 Leo Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
JP2014508104A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
EP2643290A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
EP2643292A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
IN2015MN00421A (pl) * 2012-08-27 2015-09-04 Lupin Ltd
IL263494B2 (en) 2016-06-13 2024-01-01 Syneurx Int Taiwan Corp Use of lithium benzoate to treat disorders of the central nervous system
BR112022011127A2 (pt) * 2019-12-09 2022-08-23 Beijing Tuo Jie Biopharmaceutical Co Ltd Composto agonista do receptor de detecção de cálcio e aplicação do mesmo
KR20230106582A (ko) 2020-08-04 2023-07-13 캘시리틱스 테라퓨틱스, 인코포레이티드 트리페닐 칼실리틱 화합물의 제형
CA3192684A1 (en) * 2020-09-18 2022-03-24 Simon BRUCE Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633760A (pl) * 1963-06-18
DD207203A1 (de) * 1982-06-21 1984-02-22 Peter Meisel Verfahren zur herstellung von epoxypropylethern
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5276008A (en) * 1990-08-09 1994-01-04 Bayer Aktiengesellschaft Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones
IL126458A (en) 1996-04-09 2004-06-20 Nps Pharma Inc Calcium receptor inhibiting calcilytic compounds
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
EP0827746B1 (en) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
AR018177A1 (es) 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
US20020052509A1 (en) 1998-04-08 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds and method of use
US6334338B1 (en) 1998-07-02 2002-01-01 Lucent Technologies Inc. Sol gel process of making a fiber preform with removal of oxide particles
EP1112073A4 (en) 1998-08-12 2002-10-25 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
JP2002522532A (ja) 1998-08-12 2002-07-23 スミスクライン・ビーチャム・コーポレイション カルシウム分解化合物
CZ20011394A3 (cs) * 1998-10-23 2001-12-12 F. Hoffmann-La Roche Ag Derivát bicyklických, dusík obsahujících heterocyklických sloučenin, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
JP2003508586A (ja) * 1999-08-27 2003-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー 迅速に作用する処方成分、それらの成分を使用する組成物および洗濯方法
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
KR20030017642A (ko) 2000-07-21 2003-03-03 스미스클라인 비참 코포레이션 칼실리틱 화합물
ATE411275T1 (de) * 2000-08-11 2008-10-15 Japan Tobacco Inc Calciumrezeptor-antagonisten
ES2273909T3 (es) 2000-10-25 2007-05-16 Smithkline Beecham Corporation Compuestos calciliticos.
PL365643A1 (pl) 2000-10-25 2005-01-10 Smithkline Beecham Corporation Wapniolityczne związki
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
EP1630157A4 (en) * 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR

Also Published As

Publication number Publication date
ZA200505587B (en) 2006-09-27
AU2004232604B2 (en) 2007-09-13
PE20050460A1 (es) 2005-07-08
JPWO2004094362A1 (ja) 2006-07-13
EP2189439A3 (en) 2011-05-04
NO20054868L (no) 2005-12-20
AU2004232604A1 (en) 2004-11-04
AR044075A1 (es) 2005-08-24
RU2005123985A (ru) 2006-01-27
TWI329628B (en) 2010-09-01
EP2308828A3 (en) 2013-05-22
IL169575A0 (en) 2007-07-04
DK1619180T3 (da) 2010-03-29
CY1109880T1 (el) 2014-09-10
CO5640091A2 (es) 2006-05-31
US20090326058A1 (en) 2009-12-31
AU2004232604C1 (en) 2008-06-05
NZ541188A (en) 2008-01-31
SI1619180T1 (sl) 2010-04-30
TW200505823A (en) 2005-02-16
EP1619180A1 (en) 2006-01-25
CN1741984A (zh) 2006-03-01
US20050032796A1 (en) 2005-02-10
EP1619180A4 (en) 2006-05-24
NO20054868D0 (no) 2005-10-21
AU2004232604B8 (en) 2004-11-04
RU2315036C2 (ru) 2008-01-20
DE602004024668D1 (de) 2010-01-28
EP1619180B1 (en) 2009-12-16
CN100577633C (zh) 2010-01-06
ATE452121T1 (de) 2010-01-15
MXPA05007609A (es) 2005-09-30
HRP20100042T1 (hr) 2010-02-28
HK1083096A1 (en) 2006-06-23
US7304174B2 (en) 2007-12-04
US20080255042A1 (en) 2008-10-16
MY138734A (en) 2009-07-31
IL169575A (en) 2011-07-31
JP3751312B2 (ja) 2006-03-01
EP2189439A2 (en) 2010-05-26
EP2308828A2 (en) 2011-04-13
ES2337576T3 (es) 2010-04-27
PT1619180E (pt) 2009-12-29
CA2513738A1 (en) 2004-11-04
WO2004094362A1 (ja) 2004-11-04
US20120301552A1 (en) 2012-11-29
KR100696927B1 (ko) 2007-03-20
KR20050094047A (ko) 2005-09-26
BRPI0407097A (pt) 2006-01-24
CL2004000868A1 (es) 2005-01-21
CN101723921A (zh) 2010-06-09
CA2513738C (en) 2010-04-06
AU2004232604A8 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
HK1083096A1 (en) Casr antagonist casr
ZA200603879B (en) Substituted indazole-O-glucosides
IL175490A0 (en) Substituted indazole-o-glucosides
ZA200603880B (en) Substituted indole-O-glucosides
EP1680131A4 (en) SUBSTITUTED INDOLE-O-GLUCOSIDES
DE502004003476D1 (en) Standfuss
DE502004006683D1 (en) Injection-locked-oscillator-schaltkreis
DE602004013036D1 (en) Us
ZA200600430B (en) Substituted spirobenzazepines
DE502004004146D1 (en) Pyrazolverbindungen
DE112004002769D2 (en) Schienengeführtes transportsystem
DE10394343D2 (en) Berührungslose biometrische erkennung
EP1664013A4 (en) CALCILYTIC COMPOUNDS
GB2398601B (en) Catch
GB0409607D0 (en) Antagonist
GB0308744D0 (en) Counterweights
AU2834P (en) Baltinblus Gaura lindheimeri
AU2833P (en) Baltinrose Gaura lindheimeri
GB0301104D0 (en) Freeze-cast structures
GB0523346D0 (en) Structures
GB0310882D0 (en) Novel structures
GB0307522D0 (en) Nets
GB0307336D0 (en) Nets
GB0316354D0 (en) Receptors
GB0308309D0 (en) Receptors